Table 2.
Patient-related outcomes of all patients during 1 year of follow-up a
| |
Early remission |
Arm 1 |
Arm 2 |
|
OP group |
|---|---|---|---|---|---|
| Patient characteristics at follow-up visits | (N = 387) | (N = 83) | (N = 78) | P | (N = 50) |
| 4 months |
|
|
|
|
|
| DAS |
0.97 (0.40) |
2.49 (0.63) |
2.57 (0.68) |
0.47 |
2.31 (0.63) |
| HAQ |
0.23 (0.33) |
0.86 (0.57) |
0.88 (0.57) |
0.77 |
0.73 (0.68) |
| MACTAR |
58.2 (15.7) |
52.8 (15.1) |
48.9 (18.8) |
0.14 |
51.6 (14.1) |
| MCS |
52.4 (8.0) |
48.8 (9.9) |
50.7 (10.8) |
0.26 |
49.8 (10.5) |
| PCS |
51.7 (8.1) |
39.4 (9.7) |
38.1 (9.4) |
0.44 |
42.5 (9.4) |
| VASgl, mm |
14 (14) |
37 (21) |
39 (21) |
0.61 |
28 (22) |
| VASda, mm |
12 (15) |
42 (24) |
43 (24) |
0.74 |
32 (25) |
| VASpain, mm |
10 (14) |
39 (24) |
38 (24) |
0.79 |
27 (24) |
| VASms, mm |
11 (17) |
40 (27) |
39 (27) |
0.78 |
32 (30) |
| 8 months |
|
|
|
|
|
| DAS |
1.29 (0.69) |
1.97 (0.87) |
2.01 (0.91) |
0.77 |
2.02 (0.84) |
| HAQ |
0.35 (0.44) |
0.74 (0.61) |
0.81 (0.64) |
0.51 |
0.68 (0.59) |
| MACTAR |
56.4 (15.7) |
55.8 (14.7) |
54.5 (16.1) |
0.60 |
48.9 (19.9) |
| MCS |
52.9 (8.4) |
46.6 (17.9) |
48.7 (10.3) |
0.85 |
48.5 (13.0) |
| PCS |
48.9 (9.1) |
42.8 (10.9) |
42.5 (11.0) |
0.26 |
43.7 (9.5) |
| VASgl, mm |
20 (20) |
33 (23) |
34 (21) |
0.75 |
30 (23) |
| VASda, mm |
22 (23) |
39 (26) |
33 (24) |
0.20 |
35 (25) |
| VASpain, mm |
19 (23) |
35 (26) |
31 (25) |
0.36 |
32 (24) |
| VASms, mm |
24 (26) |
34 (29) |
37 (28) |
0.51 |
40 (27) |
| 1 year |
|
|
|
|
|
| DAS |
1.31 (0.78) |
2.07 (0.89) |
1.77 (0.90) |
0.04 |
2.20 (0.83) |
| HAQ |
0.38 (0.49) |
0.87 (0.66) |
0.81 (0.66) |
0.60 |
0.77 (0.65) |
| MACTAR |
63.0 (9.4) |
59.2 (10.3) |
60.4 (11.9) |
0.54 |
59.7 (11.21) |
| MCS |
53.1 (8.6) |
50.5 (10.3) |
50.5 (10.1) |
0.97 |
50.4 (11.9) |
| PCS |
48.6 (9.8) |
39.9 (10.3) |
43.0 (11.4) |
0.10 |
42.6 (10.9) |
| VASgl, mm |
20 (21) |
33 (23) |
27 (20) |
0.10 |
33 (24) |
| VASda, mm |
24 (26) |
42 (29) |
31 (26) |
0.02 |
34 (27) |
| VASpain, mm |
21 (23) |
38 (28) |
28 (25) |
0.02 |
28 (25) |
| VASms, mm |
25 (26) |
41 (31) |
33 (27) |
0.96 |
39 (30) |
| Remission (DAS <1.6) | 263 (68) | 21 (25) | 32 (41) | 0.01 | 11 (22) |
aData are means ± SD, medians (IQR) or numbers (%) as appropriate. ACPA: anticitrullinated protein antibody; DAS: Disease Activity Score; HAQ: Health Assessment Questionnaire; MACTAR: McMaster Toronto Arthritis Patient Preference Questionnaire; MCS: Mental Component Score on the 36-Item Short Form Health Survey; PSC: Physical Component Score on the 36-Item Short Form Health Survey; RA2010: rheumatoid arthritis according to the 2010 American College of Rheumatology and European League against Rheumatism classification criteria; VASda: disease activity; VASgl: global health; VASms: morning stiffness; VASpain: pain. P-value represents the difference in mean scores and remission rates between arms 1 and 2.